Vascular endothelial growth factor serum level as a diagnostic and prognostic marker for colorectal carcinoma

Medhat Asem, A. T. Abbas, Mohamed Al-Hemaly, Asem Shalaby, Mohamed Sami

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Colorectal cancer is a major cause of cancer death and the main line of treatment is still radical surgery but this necessitates a very early diagnosis. Serum markers currently used in clinical practice for colorectal cancer are carcinoemberyonic antigen (CEA) and carbohydrate antigen (CA19-9). Both are used during surveillance and as prognostic measures for disease-free survival but not for diagnostic or screening purposes because of insufficient sensitivity and specificity. Therefore there is an urgent need for a serum marker that can help in early diagnosis. Angiogenesis plays a key role in tumor growth and progression and its targeting has been shown to be an effective anti-tumour measure. Vascular endothelial growth factor (VEGF) is one of the major factors that stimulate angiogenesis and its serum concentration could be a prognostic marker in solid tumors and has been described in a large variety of human malignancies. The aim of this work was to investigate the expression of Vascular Endothelial Growth Factor (VEGF) in colorectal cancer (CRC) patients; and correlate the findings with the patients' clinicopathologic features. Serum level of VEGF was determined in 68 patients and in 10 healthy controls and was compared to the levels of CEA and CA19-9. The results showed that serum level of VEGF were elevated in CRC patients and was significantly correlated with the levels of CEA and CA19-9. In conclusion VEGF serum level determination can be a good diagnostic marker for CRC and also open the way for VEGF inhibitors to be used as targeted therapy in CRC patients.

Original languageEnglish
Pages (from-to)1975-1981
Number of pages7
JournalLife Science Journal
Volume10
Issue number3
Publication statusPublished - Jul 2013

Fingerprint

Vascular Endothelial Growth Factor A
Colorectal Neoplasms
Serum
Antigens
Tumors
Neoplasms
Early Diagnosis
Biomarkers
Angiogenesis Inducing Agents
Surgery
Disease-Free Survival
Cause of Death
Screening
Carbohydrates
Sensitivity and Specificity
Therapeutics
Growth

Keywords

  • CA19-9
  • CEA
  • Rectal carcinoma
  • VEGF

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Vascular endothelial growth factor serum level as a diagnostic and prognostic marker for colorectal carcinoma. / Asem, Medhat; Abbas, A. T.; Al-Hemaly, Mohamed; Shalaby, Asem; Sami, Mohamed.

In: Life Science Journal, Vol. 10, No. 3, 07.2013, p. 1975-1981.

Research output: Contribution to journalArticle

Asem, Medhat ; Abbas, A. T. ; Al-Hemaly, Mohamed ; Shalaby, Asem ; Sami, Mohamed. / Vascular endothelial growth factor serum level as a diagnostic and prognostic marker for colorectal carcinoma. In: Life Science Journal. 2013 ; Vol. 10, No. 3. pp. 1975-1981.
@article{121eb83f34d144e5b79c4e80ed973fc2,
title = "Vascular endothelial growth factor serum level as a diagnostic and prognostic marker for colorectal carcinoma",
abstract = "Colorectal cancer is a major cause of cancer death and the main line of treatment is still radical surgery but this necessitates a very early diagnosis. Serum markers currently used in clinical practice for colorectal cancer are carcinoemberyonic antigen (CEA) and carbohydrate antigen (CA19-9). Both are used during surveillance and as prognostic measures for disease-free survival but not for diagnostic or screening purposes because of insufficient sensitivity and specificity. Therefore there is an urgent need for a serum marker that can help in early diagnosis. Angiogenesis plays a key role in tumor growth and progression and its targeting has been shown to be an effective anti-tumour measure. Vascular endothelial growth factor (VEGF) is one of the major factors that stimulate angiogenesis and its serum concentration could be a prognostic marker in solid tumors and has been described in a large variety of human malignancies. The aim of this work was to investigate the expression of Vascular Endothelial Growth Factor (VEGF) in colorectal cancer (CRC) patients; and correlate the findings with the patients' clinicopathologic features. Serum level of VEGF was determined in 68 patients and in 10 healthy controls and was compared to the levels of CEA and CA19-9. The results showed that serum level of VEGF were elevated in CRC patients and was significantly correlated with the levels of CEA and CA19-9. In conclusion VEGF serum level determination can be a good diagnostic marker for CRC and also open the way for VEGF inhibitors to be used as targeted therapy in CRC patients.",
keywords = "CA19-9, CEA, Rectal carcinoma, VEGF",
author = "Medhat Asem and Abbas, {A. T.} and Mohamed Al-Hemaly and Asem Shalaby and Mohamed Sami",
year = "2013",
month = "7",
language = "English",
volume = "10",
pages = "1975--1981",
journal = "Life Science Journal",
issn = "1097-8135",
publisher = "Zhengzhou University",
number = "3",

}

TY - JOUR

T1 - Vascular endothelial growth factor serum level as a diagnostic and prognostic marker for colorectal carcinoma

AU - Asem, Medhat

AU - Abbas, A. T.

AU - Al-Hemaly, Mohamed

AU - Shalaby, Asem

AU - Sami, Mohamed

PY - 2013/7

Y1 - 2013/7

N2 - Colorectal cancer is a major cause of cancer death and the main line of treatment is still radical surgery but this necessitates a very early diagnosis. Serum markers currently used in clinical practice for colorectal cancer are carcinoemberyonic antigen (CEA) and carbohydrate antigen (CA19-9). Both are used during surveillance and as prognostic measures for disease-free survival but not for diagnostic or screening purposes because of insufficient sensitivity and specificity. Therefore there is an urgent need for a serum marker that can help in early diagnosis. Angiogenesis plays a key role in tumor growth and progression and its targeting has been shown to be an effective anti-tumour measure. Vascular endothelial growth factor (VEGF) is one of the major factors that stimulate angiogenesis and its serum concentration could be a prognostic marker in solid tumors and has been described in a large variety of human malignancies. The aim of this work was to investigate the expression of Vascular Endothelial Growth Factor (VEGF) in colorectal cancer (CRC) patients; and correlate the findings with the patients' clinicopathologic features. Serum level of VEGF was determined in 68 patients and in 10 healthy controls and was compared to the levels of CEA and CA19-9. The results showed that serum level of VEGF were elevated in CRC patients and was significantly correlated with the levels of CEA and CA19-9. In conclusion VEGF serum level determination can be a good diagnostic marker for CRC and also open the way for VEGF inhibitors to be used as targeted therapy in CRC patients.

AB - Colorectal cancer is a major cause of cancer death and the main line of treatment is still radical surgery but this necessitates a very early diagnosis. Serum markers currently used in clinical practice for colorectal cancer are carcinoemberyonic antigen (CEA) and carbohydrate antigen (CA19-9). Both are used during surveillance and as prognostic measures for disease-free survival but not for diagnostic or screening purposes because of insufficient sensitivity and specificity. Therefore there is an urgent need for a serum marker that can help in early diagnosis. Angiogenesis plays a key role in tumor growth and progression and its targeting has been shown to be an effective anti-tumour measure. Vascular endothelial growth factor (VEGF) is one of the major factors that stimulate angiogenesis and its serum concentration could be a prognostic marker in solid tumors and has been described in a large variety of human malignancies. The aim of this work was to investigate the expression of Vascular Endothelial Growth Factor (VEGF) in colorectal cancer (CRC) patients; and correlate the findings with the patients' clinicopathologic features. Serum level of VEGF was determined in 68 patients and in 10 healthy controls and was compared to the levels of CEA and CA19-9. The results showed that serum level of VEGF were elevated in CRC patients and was significantly correlated with the levels of CEA and CA19-9. In conclusion VEGF serum level determination can be a good diagnostic marker for CRC and also open the way for VEGF inhibitors to be used as targeted therapy in CRC patients.

KW - CA19-9

KW - CEA

KW - Rectal carcinoma

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84884728495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884728495&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 1975

EP - 1981

JO - Life Science Journal

JF - Life Science Journal

SN - 1097-8135

IS - 3

ER -